Genomic Biomarkers of Survival in Patients with Adenocarcinoma of the Uterine Cervix Receiving Chemoradiotherapy.

International Journal of Molecular Sciences
YING-CHUN LINJan-Gowth Chang

Abstract

This study investigated the prognostic effects of genomic biomarkers for predicting chemoradiotherapy (CRT)-based treatment outcomes in patients with adenocarcinoma (AC) of the uterine cervix. In all, 21 patients receiving definitive CRT were included. In accordance with the International Federation of Gynecology and Obstetrics (FIGO) staging system, 5, 8, and 8 patients were classified as having stage IB3, II, and III disease, respectively. Pretreatment biomarkers were analyzed using tissue microarrays from biopsy specimens. Genomic alterations were examined by next-generation sequencing (NGS). The outcome endpoints were disease-free survival (DFS), distant metastasis-free survival (DMFS), and local relapse-free survival (LRFS). A Cox regression model was used to examine the prognostic effects of the biomarkers and clinical parameters. The presence of myeloid cell leukemia-1 (MCL1) gene amplification and a lower immunohistochemical (IHC) marker of tumor necrotic factor alpha (TNF-α) H-score were two prognostic factors for inferior DFS. The four-year DFS was 28% and 68% for patients with or without MCL1 copy number gain, respectively (p = 0.028). In addition, MCL1 amplification predicted poor DMFS. A lower tumor mutation number...Continue Reading

References

Mar 10, 2001·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·C.-H. LaiJ.-D. Lin
Dec 12, 2003·Nature·Joseph T OpfermanStanley J Korsmeyer
Dec 8, 2004·Gynecologic Oncology·Stephen A ContagEric S Calhoun
Mar 2, 2006·Journal of the National Cancer Institute·Xavier CastellsaguéUNKNOWN International Agency for Research on Cancer Multicenter Cervical Cancer Study Group
Aug 19, 2009·The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society·Kingshuk Roy ChoudhuryJoseph G Rajendran
Nov 3, 2009·Gynecologic Oncology·Lilian T GienGillian Thomas
Jun 15, 2010·FEBS Letters·Luke W ThomasSteven W Edwards
Jun 15, 2010·International Journal of Radiation Oncology, Biology, Physics·Yi-Ting HuangJi-Hong Hong
Feb 8, 2011·CA: a Cancer Journal for Clinicians·Ahmedin JemalDavid Forman
Oct 5, 2015·International Journal of Gynaecology and Obstetrics : the Official Organ of the International Federation of Gynaecology and Obstetrics·Adriana BermudezEric Leung
Jun 23, 2016·Applied Immunohistochemistry & Molecular Morphology : AIMM·Charlotte RoachKarina Kulangara
Jul 22, 2016·Cancer Immunology Research·Mariko IshibashiKoiti Inokuchi
Jan 24, 2017·Nature·UNKNOWN Cancer Genome Atlas Research NetworkUNKNOWN Washington University in St Louis
Nov 15, 2018·OncoTargets and Therapy·Weiguo XiangLongchuan Bai
Jul 17, 2019·Journal for Immunotherapy of Cancer·Laura FancelloLuca Mazzarella

❮ Previous
Next ❯

Citations

Jan 21, 2021·Expert Review of Anticancer Therapy·Christine GennigensGuy Jerusalem

❮ Previous
Next ❯

Methods Mentioned

BETA
exome sequencing
PCR
biopsy
hysterectomy

Software Mentioned

FATHMM
PolyPhen
Samtools
SIFT
Time Analysis
Varscan
SPSS
bcl2fastq Conversion
smCounter
Real

Related Concepts

Related Feeds

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.